These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

201 related items for PubMed ID: 12939666

  • 21. Role of immunohistochemical identification of Her-2/neu and detection of variability in overexpression in pancreatic carcinoma.
    Koka V, Potti A, Koch M, Fraiman G, Mehdi S, Levitt R.
    Anticancer Res; 2002; 22(3):1593-7. PubMed ID: 12168842
    [Abstract] [Full Text] [Related]

  • 22. Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma?
    Gandour-Edwards R, Lara PN, Folkins AK, LaSalle JM, Beckett L, Li Y, Meyers FJ, DeVere-White R.
    Cancer; 2002 Sep 01; 95(5):1009-15. PubMed ID: 12209684
    [Abstract] [Full Text] [Related]

  • 23. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
    Badve S, Turbin D, Thorat MA, Morimiya A, Nielsen TO, Perou CM, Dunn S, Huntsman DG, Nakshatri H.
    Clin Cancer Res; 2007 Aug 01; 13(15 Pt 1):4415-21. PubMed ID: 17671124
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Prevalence and management of HER2/neu-positive early breast cancer in a single institution following availability of adjuvant trastuzumab.
    Chan A, McGregor SR.
    Intern Med J; 2012 Mar 01; 42(3):267-74. PubMed ID: 21241440
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. A comparative assessment of HER2 status in operable breast cancer by real-time RT-PCR and by immunohistochemistry.
    Potemski P, Płuciennik E, Bednarek AK, Kusińska R, Pasz-Walczak G, Jesionek-Kupnicka D, Watala C, Kordek R.
    Med Sci Monit; 2006 Dec 01; 12(12):MT57-61. PubMed ID: 17136015
    [Abstract] [Full Text] [Related]

  • 31. Central nervous system relapse in patients with breast cancer is associated with advanced stages, with the presence of circulating occult tumor cells and with the HER2/neu status.
    Souglakos J, Vamvakas L, Apostolaki S, Perraki M, Saridaki Z, Kazakou I, Pallis A, Kouroussis C, Androulakis N, Kalbakis K, Millaki G, Mavroudis D, Georgoulias V.
    Breast Cancer Res; 2006 Dec 01; 8(4):R36. PubMed ID: 16846533
    [Abstract] [Full Text] [Related]

  • 32. Do we need HER-2/neu testing for all patients with primary breast carcinoma?
    Taucher S, Rudas M, Mader RM, Gnant M, Dubsky P, Bachleitner T, Roka S, Fitzal F, Kandioler D, Sporn E, Friedl J, Mittlböck M, Jakesz R.
    Cancer; 2003 Dec 15; 98(12):2547-53. PubMed ID: 14669272
    [Abstract] [Full Text] [Related]

  • 33. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.
    Scandinavian Breast Group Trial 9401Laboratory of Cancer Biology, Institute of Medical Technology, and Department of Oncology, Tampere University and Tampere University Hospital, Tampere, Finland., Tanner M, Isola J, Wiklund T, Erikstein B, Kellokumpu-Lehtinen P, Malmström P, Wilking N, Nilsson J, Bergh J.
    J Clin Oncol; 2006 Jun 01; 24(16):2428-36. PubMed ID: 16682728
    [Abstract] [Full Text] [Related]

  • 34. Long-term prognostic significance of HER-2/neu in untreated node-negative breast cancer depends on the method of testing.
    Schmidt M, Lewark B, Kohlschmidt N, Glawatz C, Steiner E, Tanner B, Pilch H, Weikel W, Kölbl H, Lehr HA.
    Breast Cancer Res; 2005 Jun 01; 7(2):R256-66. PubMed ID: 15743506
    [Abstract] [Full Text] [Related]

  • 35. Patterns of relapse and metastatic spread in HER2-overexpressing breast cancer according to estrogen receptor status.
    Park YH, Lee S, Cho EY, Choi YL, Lee JE, Nam SJ, Yang JH, Ahn JS, Im YH.
    Cancer Chemother Pharmacol; 2010 Aug 01; 66(3):507-16. PubMed ID: 19956951
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Breast carcinoma in pregnant women: assessment of clinicopathologic and immunohistochemical features.
    Middleton LP, Amin M, Gwyn K, Theriault R, Sahin A.
    Cancer; 2003 Sep 01; 98(5):1055-60. PubMed ID: 12942575
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S, Chen W, Tchou J, Mavi A, Cermik T, Czerniecki B, Schnall M, Alavi A.
    Cancer; 2008 Mar 01; 112(5):995-1000. PubMed ID: 18098228
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.